<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560118</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574147</org_study_id>
    <secondary_id>CLCC-MGFOT-1</secondary_id>
    <secondary_id>INCA-RECF0287</secondary_id>
    <nct_id>NCT00560118</nct_id>
  </id_info>
  <brief_title>Fotemustine in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase II Study of the Predictive Value of the Expression of Tumoral MGMT With Respect to the Therapeutic Response of Fotemustine in Patients With Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fotemustine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors&#xD;
      predict how well patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying fotemustine to see how well it works in treating&#xD;
      patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the relationship between MGMT expression and response to fotemustine in patients&#xD;
           with metastatic malignant melanoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Establish a value for MGMT expression below which fotemustine has a strong probability&#xD;
           of effectiveness.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive induction chemotherapy comprising fotemustine IV over 1 hour on days 1, 8,&#xD;
      and 15. Beginning 5 weeks later, patients achieving stable or objective response receive&#xD;
      maintenance chemotherapy comprising fotemustine IV over 1 hour once every 3 weeks for 6&#xD;
      courses.&#xD;
&#xD;
      Tissue samples are collected at baseline to assess level of MGMT expression by PCR.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship between MGMT expression and response to fotemustine</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Value for MGMT expression below which fotemustine has a strong probability of effectiveness</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fotemustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic malignant melanoma, meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  Metastatic lymph nodes or skin allowing for surgical resection&#xD;
&#xD;
               -  At least 1 metastatic lesion (lymph nodes, skin, visceral, brain)&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  ANC &gt; 2 x 10^9/L&#xD;
&#xD;
          -  Platelet count &gt; 100 x 10^9/L&#xD;
&#xD;
          -  Transaminases ≤ 2.5 times normal&#xD;
&#xD;
          -  Alkaline phosphate ≤ 2.5 times normal&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No severe uncontrolled infection&#xD;
&#xD;
          -  No other prior or concurrent malignancy (except basal cell or squamous cell carcinoma&#xD;
             in situ of the cervix that was curatively treated)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior adjuvant therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 30 days since prior participation in another clinical trial&#xD;
&#xD;
          -  No prior or concurrent prophylactic phenytoin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Cupissol, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>November 16, 2007</study_first_submitted>
  <study_first_submitted_qc>November 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2007</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fotemustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

